Patents by Inventor Yolande Chvatchko

Yolande Chvatchko has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Polypeptides that bind to IL-17A, IL-17F and/or IL17-A/F and methods of treatment using same
    Patent number: 11773159
    Abstract: The present disclosure relates to amino acid sequences that are directed against (as defined herein) any of IL-17A, IL-17F and/or IL-17A/F including combinations thereof, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Grant
    Filed: September 29, 2020
    Date of Patent: October 3, 2023
    Assignee: Merck Patent GmbH
    Inventors: Heidi Rommelaere, Joost Alexander Kolkman, Michael John Scott Saunders, Ann Union, Yolande Chvatchko, Amanda E. I. Proudfoot, Alain Vicari, Denis Bruniquel, Laurent Chevalet, Olivier Leger
  • AMINO ACID SEQUENCES DIRECTED AGAINST IL-17A, IL-17F AND/OR IL-17A/F AND POLYPEPTIDES COMPRISING THE SAME
    Publication number: 20220195031
    Abstract: The present disclosure relates to amino acid sequences that are directed against (as defined herein) any of IL-17A, IL-17F and/or IL-17A/F including combinations thereof, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Application
    Filed: February 24, 2022
    Publication date: June 23, 2022
    Applicant: Merck Patent GmbH
    Inventors: Heidi ROMMELAERE, Joost Alexander KOLKMAN, Michael John Scott SAUNDERS, Ann UNION, Yolande CHVATCHKO, Amanda E.I. PROUDFOOT, Alain VICARI, Denis BRUNIQUEL, Laurent CHEVALET, Olivier LEGER
  • AMINO ACID SEQUENCES DIRECTED AGAINST IL-17A, IL-17F AND/OR IL-17A/F AND POLYPEPTIDES COMPRISING THE SAME
    Publication number: 20210130452
    Abstract: The present disclosure relates to amino acid sequences that are directed against (as defined herein) any of IL-17A, IL-17F and/or IL-17A/F including combinations thereof, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Application
    Filed: September 29, 2020
    Publication date: May 6, 2021
    Applicant: Merck Patent GmbH
    Inventors: Heidi ROMMELAERE, Joost Alexander KOLKMAN, Michael John Scott SAUNDERS, Ann UNION, Yolande CHVATCHKO, Amanda E.I. PROUDFOOT, Alain VICARI, Denis BRUNIQUEL, Laurent CHEVALET, Olivier LEGER
  • Polypeptides that bind to IL-17A, IL-17F and/or IL17-A/F and methods of treatment using same
    Patent number: 10829552
    Abstract: The present disclosure relates to amino acid sequences that are directed against (as defined herein) any of IL-17A, IL-17F and/or IL-17A/F including combinations thereof, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Grant
    Filed: June 7, 2018
    Date of Patent: November 10, 2020
    Assignee: Merck Patent GmbH
    Inventors: Heidi Rommelaere, Joost Alexander Kolkman, Michael John Scott Saunders, Ann Union, Yolande Chvatchko, Amanda E. I. Proudfoot, Alain Vicari, Denis Bruniquel, Laurent Chevalet, Olivier Leger
  • Antibodies specific for MMP9
    Patent number: 10364296
    Abstract: The present invention relates to new proteins that bind to MMP9 and comprise at least one fragment of a heavy chain variable region and/or at least one fragment of a light chain variable region of an antibody. In particular, the MMP9 binding proteins according to the invention are able to neutralize MMP9 activity and are useful in the prevention and/or treatment of inflammatory and/or autoimmune diseases or cancers. In particular, the MMP9 binding proteins according to the invention are useful in diagnosis of MMP9-related disorders.
    Type: Grant
    Filed: August 13, 2015
    Date of Patent: July 30, 2019
    Assignees: CALYPSO BIOTECH SA, MERCK PATENT GMBH
    Inventors: Yolande Chvatchko Missotten, Laurence Goffin, Olivier Leger, Steven M. Dunn, Christine Power, Kinsey Maundrell
  • AMINO ACID SEQUENCES DIRECTED AGAINST IL-17A, IL-17F AND/OR IL-17A/F AND POLYPEPTIDES COMPRISING THE SAME
    Publication number: 20190100584
    Abstract: The present disclosure relates to amino acid sequences that are directed against (as defined herein) any of IL-17A, IL-17F and/or IL-17A/F including combinations thereof, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Application
    Filed: June 7, 2018
    Publication date: April 4, 2019
    Applicant: Merck Patent GmbH
    Inventors: Heidi ROMMELAERE, Joost Alexander KOLKMAN, Michael John Scott SAUNDERS, Ann UNION, Yolande CHVATCHKO, Amanda E.I. PROUDFOOT, Alain VICARI, Denis BRUNIQUEL, Laurent CHEVALET, Olivier LEGER
  • Lactococcus lactis producing TSLP or IL-25 and their uses as probiotics and therapeutics
    Patent number: 10238697
    Abstract: The present invention relates to recombinant Lactococcus lactis bacteria expressing and secreting TSLP or IL-25 or a combination thereof, and their use as probiotics or therapeutic agents, especially for use in the treatment of inflammatory diseases and disorders.
    Type: Grant
    Filed: April 12, 2016
    Date of Patent: March 26, 2019
    Assignee: ARES TRADING S.A.
    Inventors: Philippe Langella, Jean-Marc Chatel, Luis Bermudez-Humaran, Camille Aubry, Laurence Goffin, Simone Favre-Zimmerli, Yolande Chvatchko
  • Polypeptides that bind to IL-17A, IL-17F and/or IL17-A/F and method of treatment using same
    Patent number: 10017568
    Abstract: The present disclosure relates to amino acid sequences that are directed against (as defined herein) any of IL-17A, IL-17F and/or IL-17A/F including combinations thereof, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Grant
    Filed: May 4, 2012
    Date of Patent: July 10, 2018
    Assignee: Merck Patent GmbH
    Inventors: Heidi Rommelaere, Joost Alexander Kolkman, Michael John Scott Saunders, Ann Union, Yolande Chvatchko, Amanda E. I. Proudfoot, Alain Vicari, Denis Bruniquel, Laurent Chevalet, Olivier Leger
  • LACTOCOCCUS LACTIS PRODUCING TSLP OR IL-25 AND THEIR USES AS PROBIOTICS AND THERAPEUTICS
    Publication number: 20180104285
    Abstract: The present invention relates to recombinant Lactococcus lactis bacteria expressing and secreting TSLP or IL-25 or a combination thereof, and their use as probiotics or therapeutic agents, especially for use in the treatment of inflammatory diseases and disorders.
    Type: Application
    Filed: April 12, 2016
    Publication date: April 19, 2018
    Inventors: PHILIPPE LANGELLA, JEAN-MARC CHATEL, LUIS BERMUDEZ-HUMARAN, CAMILLE AUBRY, LAURENCE GOFFIN, SIMONE FAVRE-ZIMMERLI, YOLANDE CHVATCHKO
  • ANTIBODIES SPECIFIC FOR MMP9
    Publication number: 20170233495
    Abstract: The present invention relates to new proteins that bind to MMP9 and comprise at least one fragment of a heavy chain variable region and/or at least one fragment of a light chain variable region of an antibody. In particular, the MMP9 binding proteins according to the invention are able to neutralize MMP9 activity and are useful in the prevention and/or treatment of inflammatory and/or autoimmune diseases or cancers. In particular, the MMP9 binding proteins according to the invention are useful in diagnosis of MMP9-related disorders.
    Type: Application
    Filed: August 13, 2015
    Publication date: August 17, 2017
    Inventors: YOLANDE CHVATCHKO MISSOTTEN, LAURENCE GOFFIN, OLIVIER LEGER, STEVEN M. DUNN, CHRISTINE POWER, KINSEY MAUNDRELL
  • Use of IL-18BP for treatment of peripheral vascular diseases
    Patent number: 9592267
    Abstract: The invention relates to the use of an inhibitor of IL-18 in the preparation of a medicament for treatment and/or prevention of peripheral vascular diseases. The invention further relates to the use of an IL-18 inhibitor for prevention of limb amputation.
    Type: Grant
    Filed: March 13, 2003
    Date of Patent: March 14, 2017
    Assignee: MERCK SERONO SA
    Inventors: Yolande Chvatchko, Alain Tedgui, Ziad Mallat
  • Method of treating peripheral vascular diseases using IL-18 inhibitors
    Patent number: 9566313
    Abstract: The invention relates to the use of an inhibitor of IL-18 in the preparation of a medicament for treatment and/or prevention of peripheral vascular diseases. The invention further relates to the use of an IL-18 inhibitor for prevention of limb amputation.
    Type: Grant
    Filed: June 1, 2010
    Date of Patent: February 14, 2017
    Assignees: MERCK SERONO SA, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
    Inventors: Yolande Chvatchko, Alain Tedgui, Ziad Mallat
  • AMINO ACID SEQUENCES DIRECTED AGAINST IL-17A, IL-17F AND/OR IL17-A/F AND POLYPEPTIDES COMPRISING THE SAME
    Publication number: 20140314743
    Abstract: The present disclosure relates to amino acid sequences that are directed against (as defined herein) any of IL-17A, IL-17F and/or IL-17A/F including combinations thereof, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Application
    Filed: May 4, 2012
    Publication date: October 23, 2014
    Applicant: Merck Patent GmbH
    Inventors: Heidi Rommelaere, Joost Alexander Kolkman, Michael John Scott Saunders, Ann Union, Yolande Chvatchko, Amanda E.I. Proudfoot, Alain Vicari, Denis Bruniquel, Laurent Chevalet, Olivier Leger
  • Use of IL-18BP isoforms for the treatment and/or prevention of neurological inflammatory diseases
    Patent number: 8128920
    Abstract: The invention relates to the use of an IL18-BP isoform that does not bind to IL18, or of an agonist thereof, for treatment or prevention of a neurological and/or inflammatory disease. Preferred isoforms for use in the frame of the invention include IL-18BPb and IL-18BPd.
    Type: Grant
    Filed: June 2, 2006
    Date of Patent: March 6, 2012
    Assignee: Merck Serono SA
    Inventors: Yves Sagot, Yolande Chvatchko, Anne Corbaz
  • Use of soluble CD164 in inflammatory and/or autoimmune disorders
    Patent number: 8075894
    Abstract: The present invention relates to novel therapeutic uses of soluble proteins comprising the extracellular region of human CD164, in particular for treating inflammatory and/or autoimmune disorders.
    Type: Grant
    Filed: December 22, 2008
    Date of Patent: December 13, 2011
    Assignee: Merck Serono SA
    Inventor: Yolande Chvatchko
  • USE OF IL-18 INHIBITORS FOR TREATMENT AND/OR PREVENTION OF PERIPHERAL VASCULAR DISEASES
    Publication number: 20100291028
    Abstract: The invention relates to the use of an inhibitor of IL-18 in the preparation of a medicament for treatment and/or prevention of peripheral vascular diseases. The invention further relates to the use of an IL-18 inhibitor for prevention of limb amputation.
    Type: Application
    Filed: June 1, 2010
    Publication date: November 18, 2010
    Applicants: MERCK SERONO SA, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
    Inventors: Yolande Chvatchko, Alain Tedgui, Ziad Mallat
  • Method of treatment comprising administration of a cytokine antagonist molecule
    Patent number: 7803383
    Abstract: This invention relates to novel uses of a protein sequence (INSP052EC), herein identified as an immunoglobulin domain-containing cell surface recognition, in the diagnosis, prevention and treatment of diseases, in particular those related to the excessive expression and/or secretion of cytokines.
    Type: Grant
    Filed: November 12, 2004
    Date of Patent: September 28, 2010
    Assignee: Ares Trading S.A.
    Inventors: Richard Joseph Fagan, Andrew Robert Davids, Christopher Benjamin Phelps, Christine Power, Ursula Boschert, Yolande Chvatchko
  • Benzazole derivatives for the treatment of scleroderma
    Patent number: 7776854
    Abstract: The present invention is related to the use of benzazole derivatives of formula (I) for the treatment and/or prevention of scleroderma and its therapeutic implications selected in the group consisting of systemic sclerosis, scleroderma-like disorders, sine scleroderma, liver cirrhosis, interstitial pulmonary fibrosis, Dupuytren's contracture, keloid and other scarring/wound healing abnormalities, postoperative adhesions and reactive fibrosis, as well as chronic heart failure, in particular after myocardial infarction.
    Type: Grant
    Filed: December 6, 2002
    Date of Patent: August 17, 2010
    Assignee: Merck Serono SA
    Inventors: Jean-Pierre Gotteland, Pascale Gaillard, Yolande Chvatchko
  • Methods for treating interleukin-18 mediated disorders with interleukin-18 binding proteins
    Patent number: 7696154
    Abstract: Interleukin-18 binding proteins which are capable of binding IL-18 and of modulating and/or blocking IL-18 activity are provided. Methods for the isolation and recombinant production, DNAs encoding them. DNA vectors expressing them, vectors useful for their expression in humans and other mammals, antibodies against them are also provided. Therapeutic uses of IL-18 binding proteins and further inhibitors of IL-18 are also provided according to the invention.
    Type: Grant
    Filed: March 15, 2007
    Date of Patent: April 13, 2010
    Assignee: Yeda Research and Development Company Ltd.
    Inventors: Daniela Novick, Charles Dinarello, Menachem Rubinstein, Soo Hyun Kim, Yolande Chvatchko, Christine Plater-Zyberk
  • Cytokine antagonist molecules
    Patent number: 7622555
    Abstract: This invention relates to a novel protein (INSP052), herein identified as an immunoglobulin domain-containing cell surface recognition molecule and to the use of this proteins and nucleic acid sequences from the encoding gene in the diagnosis, prevention and treatment of disease. The invention also relates to the identification of the extracellular domain of INSP052.
    Type: Grant
    Filed: November 12, 2003
    Date of Patent: November 24, 2009
    Assignee: Ares Trading S.A.
    Inventors: Andrew Robert Davids, Richard Joseph Fagan, Christopher Benjamin Phelps, Christine Power, Yolande Chvatchko, Ursula Boschert